| |
| |
 |
This week, authors opined about tackling medical misinformation on social media; took pro and con stances on Medicare's decision to limit coverage for Aduhelm, the controversial Alzheimer's drug; and more. You can read all of the week's essays here. The latest episode of the "First Opinion Podcast," on gender-affirming care, is also live. |
| |
| By Shikha Jain and Vineet Arora and Eve Bloomgarden Adobe While individual clinicians are tackling disinformation on social media, what's really needed is a substantive, multi-pronged approach. Read More |
| By John N. Mafi and Catherine Sarkisian Adobe Covering the use of Aduhelm for millions of Americans with Alzheimer's would have accelerated Medicare's path toward bankruptcy. Read More |
| By Dennis J. Selkoe and Jeffrey Cummings Adobe CMS's decision to limit coverage of Aduhelm is disappointing. But at least it didn't close the door to related drugs in the pipeline. Read More |
| By David C. Grabowski and Marilyn Rantz and Jasmine L. Travers Michael Probst/AP A new report from the National Academies of Sciences, Engineering, and Medicine examines the plight of nursing home care in the U.S. Read More |
| Sponsor content by Johnson & Johnson MedTech Putting medtech to work to solve the complex medical challenges How will science address the pervasive medical conditions that impact so many lives? By bringing the right voices to the table. Treating complex diseases like lung cancer – the most commonly diagnosed cancer worldwide – requires an integrated approach that blends the best of medical technology, software and biopharmaceuticals. With the brightest minds of these disciplines working together, we can pave the way to a healthier future for everyone, everywhere. Learn how here. |
| By Patrick Skerrett This week, "The First Opinion Podcast" explores why a diagnosis of "gender dysphoria" shouldn't be needed to cover gender-affirming care. Read More |
| By Nicole Paraggio and Nicole van Poppel and Selen Karaca-Griffin Abobe Transforming R&D has a pivotal role to play in exponentially reducing the cost of discovering and developing new drugs. Read More |
| By Jean-François Formela and John Stanford Adobe New medicines can significantly reduce the need for expensive emergency room visits, surgeries, hospitalizations, and long-term care. Read More |
| By Travis Whitfill Adobe ARPA-H didn't get the funding or independence many pushed for, but it can still emulate DARPA's structure and principles. Read More |
| By Constantinos Michaelidis and Candra Szymanski Arturo Holmes/Getty Images Home hospital programs across the country expanded after CMS began to pay for these services in November 2020 amid the pandemic. Read More |
| By Gerard Vitti Adobe When the U.S. public health emergency ends, millions will be kicked off Medicaid, though they qualify. "Redetermination" will be challenging. Read More |
| By David M. Kent and Keren Ladin and O. Kenrik Duru Adobe Disparaging all race-aware risk prediction models is misleading when including race can sometimes improve both health outcomes and fairness. Read More |
No comments